The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives
review
OA: closed
CC0
⤵ 2 in-corpus citations
AI-generated summary
This paper reviews the benefits and risks associated with combined estrogen and progestin contraceptives.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Discussion of effective birth control methods can be a challenging process for clinicians because the adoption and consistent use of contraception may be influenced by patients' fears, myths, and misperceptions. Over the years, new progestins have been included in combination contraceptives or are used alone to provide effective contraception as well as to decrease androgenic side effects and ameliorate the symptoms of premenstrual dysphoric disorder. Alternative delivery systems and regimens have also been introduced to improve tolerability and continuance and convenience of use. This is a review of estrogen and progestin combinations and their effects.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel 2009
- Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies 2008
- Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest 2010
Cited by (2)
References (36)
- Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel via openalex
- Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest via openalex
- Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies via openalex
- doi:10.1016/s0029-7844(02)02124-5 via openalex
- doi:10.1016/j.ogc.2021.07.001 via openalex
- doi:10.2307/1966452 via openalex
- doi:10.1136/bmj.b2921 via openalex
- doi:10.1097/01.aog.0000279448.62221.a8 via openalex
- doi:10.1016/s0029-7844(99)00524-4 via openalex
- doi:10.1067/mob.2002.121103 via openalex
- doi:10.1016/j.contraception.2009.07.004 via openalex
- doi:10.1136/bmj.b2890 via openalex
- doi:10.3109/13625187.2010.504313 via openalex
- W2064528665 via openalex
- doi:10.2165/00003088-200039030-00005 via openalex
- W2284147024 via openalex
- doi:10.1097/01.aog.0000250968.82370.04 via openalex
- W6679100095 via openalex
- W6683816966 via openalex
- W6695611674 via openalex
- doi:10.1016/s0015-0282(99)00205-8 via openalex
- doi:10.1016/j.mce.2003.10.030 via openalex
- doi:10.1016/s0015-0282(01)03275-7 via openalex
- doi:10.1016/j.fertnstert.2008.08.093 via openalex
- doi:10.1016/s0015-0282(00)01747-7 via openalex
- doi:10.1016/s0015-0282(01)03263-0 via openalex
- doi:10.1016/j.contraception.2005.03.005 via openalex
- doi:10.1016/j.contraception.2004.12.012 via openalex
- doi:10.1136/bmj.39289.649410.55 via openalex
- doi:10.1016/j.contraception.2006.01.001 via openalex
- doi:10.1097/aog.0b013e31818425b7 via openalex
- doi:10.1016/j.contraception.2009.09.009 via openalex
- doi:10.1016/j.contraception.2006.12.019 via openalex
- doi:10.1097/00006250-200209000-00030 via openalex
- doi:10.1016/0010-7824(96)00137-0 via openalex
- doi:10.1016/s0002-9378(98)70047-x via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-11T06:25:09.493344+00:00
License: CC0
· commercial use OK